AeroSafe, a leading provider of cold chain solutions, has successfully concluded a funding round of $43 million. The funding was led by NewSpring, through its NewSpring Healthcare strategy, which focuses on investments that have a positive impact on health outcomes across the care continuum. Existing healthcare investors such as Peloton Equity, Merck Global Health Innovation Fund, Hamilton Lane, Flexstone Capital, Wave Equity Partners, and Escalate Capital also participated in the round.
The growth capital obtained will be utilized to support AeroSafe’s ongoing customer growth, innovative product development, and increased operational capabilities.
AeroSafe is dedicated to ensuring the safe and sustainable delivery of therapeutic products. Over 45 biopharma companies rely on AeroSafe to facilitate millions of shipments to patients, providers, pharmacies, and hospital systems across 85 countries. By enhancing the reliability and sustainability of the pharmaceutical supply chain, AeroSafe is making a significant impact on the healthcare industry.
Jay McHarg, CEO of AeroSafe, expressed excitement about welcoming NewSpring to the AeroSafe team, highlighting their expertise and experience. Pete Buzy, former Chairman of Gene Therapy at Catalent, Inc., and an Advisory Partner for NewSpring’s healthcare funds, will join AeroSafe’s Board of Directors as part of the transaction.
The increasing demand for temperature-sensitive therapeutics and biologics underscores the importance of AeroSafe’s role in redefining cold chain solutions. By utilizing technology to enhance visibility and responsiveness, AeroSafe minimizes the risk of costly failures and lost drug inventory. NewSpring’s General Partner, Kapila Ratnam, emphasized the significance of AeroSafe’s technology-enabled service in addressing a critical challenge within the pharmaceutical industry and expressed enthusiasm for collaborating with the team to expand access to these vital services and drive further business growth.
